25th week of 2013 patent applcation highlights part 57 |
Patent application number | Title | Published |
20130157868 | METHOD OF JOINING SUPERCONDUCTOR MATERIALS - A method of joining superconductor materials is described. A microwave chamber including a first heat absorption plate and a second heat absorption plate corresponding to the first absorption plate is provided. A first superconductor material and a second superconductor material are disposed between the first heat absorption plate and the second heat absorption plate in the microwave chamber. The first superconductor material and the second superconductor material have an overlapping region therebetween, and a pressure is applied to the first heat absorption plate and the second heat absorption plate. Microwave power is supplied to the microwave chamber. The first heat absorption plate and the second heat absorption plate transform the microwave power into thermal energy so as to join the first superconductor material and the second superconductor material at the overlapping region. | 2013-06-20 |
20130157869 | Method for Reducing Adapter-Dimer Formation - Methods are provided for ligating a 3′ adapter and a 5′ adapter to a target polynucleotide so as to avoid adapter dimer formation. Embodiments of the methods include adding a blocking oligonucleotide after the first ligation in which a 3′ adapter is ligated to the target polynucleotide so that the blocking oligonucleotide is capable of hybridizing to excess 3′ adapter and the ligated 3′ adapter. Subsequently, a 5′ adapter is ligated to the target polynucleotide thus avoiding adapter dimer formation. | 2013-06-20 |
20130157870 | METHODS FOR OBTAINING A SEQUENCE - The invention generally relates to methods for obtaining a sequence, such as a consensus sequence or a haplotype sequence. In certain embodiments, methods of the invention involve determining an amount of amplifiable nucleic acid present in a sample, partitioning the nucleic acid based upon results of the determining step such that each partitioned portion includes, on average, a subset of unique sequences, sequencing the nucleic acid to obtain sequence reads, and assembling a consensus sequence from the reads. | 2013-06-20 |
20130157871 | METHODS FOR MULTIPLEXED SELECTION OF FUNCTIONAL LIGANDS - The present invention relates to methods for generating functional biomolecules. In one exemplary aspect of the invention, generation of functional biomolecules may be performed against multiple targets simultaneously within a single system. In general, a plurality of targets may be disposed within in a single reaction volume and a library of biomolecules, such as a nucleic acid library, may be applied to the reaction volume. The members of the library that do not bind to any of the plurality of targets under given conditions may then be partitioned. The remaining members of the library may then be marked and/or tagged, such as to identify the particular target or targets to which the member of the library binds. The binding members of the library may then be isolated and, by virtue of the marking or tagging, be matched to a particular target or targets. | 2013-06-20 |
20130157872 | IN VITRO EVOLUTION IN MICROFLUIDIC SYSTEMS - The invention describes a method for isolating one or more genetic elements encoding a gene product having a desired activity, comprising the steps of: (a) compartmentalising genetic elements into microcapsules; and (b) sorting the genetic elements which express the gene product having the desired activity; wherein at least one step is under microfluidic control. The invention enables the in vitro evolution of nucleic acids and proteins by repeated mutagenesis and iterative applications of the method of the invention. | 2013-06-20 |
20130157873 | METHODS OF ASSESSING A RISK OF DEVELOPING NECROTIZING MENINGOENCEPHALITIS - Methods of using single nucleotide polymorphisms (SNPs), SNP haplotype block, and haplotype to predict whether or not a subject will develop necrotizing meningoencephalitis (NME) and probe sets that facilitate those methods are disclosed. In particular, the subject is a canine species. | 2013-06-20 |
20130157874 | UNIVERSAL OR BROAD RANGE ASSAYS AND MULTI-TAG SAMPLE SPECIFIC DIAGNOSTIC PROCESS USING NON-OPTICAL SEQUENCING - The present invention includes a method for determining the identify of an organism or virus in a sample comprising the steps of: isolating DNA or RNA from the sample; combining the DNA or RNA directly or with one or more universal or target specific amplification primers, wherein the one or more primers are specific for one or more group of target microorganisms or virus; and amplifying the DNA, or the RNA following reverse transcription with a reverse transcriptase; and contacting the amplification product with one or more species-, organism- or virus-specific detectable marker. | 2013-06-20 |
20130157875 | METHODS FOR ASSESSING GENOMIC INSTABILITIES - The invention generally relates to methods for assessing a fetal abnormality. | 2013-06-20 |
20130157876 | Systems and Methods for Detecting Antibiotic Resistance - A robust, automated computational pipeline was used to design a system comprising a microarray for the identification of microorganisms and their antibiotic resistance profiles. This system and methods will facilitate the study of the epidemiology and microbial ecology of antibiotic resistance and be an invaluable tool to rapidly and simultaneously identify organisms and their antimicrobial resistance elements in environmental, food and clinical samples. | 2013-06-20 |
20130157877 | BIOCHIPS FOR ANALYZING NUCLEIC ACID MOLECULE DYNAMICS - The invention relates to biochips | 2013-06-20 |
20130157878 | METHOD FOR IDENTIFYING HETERO-MULTIMERIC MODIFIED UBIQUITIN PROTEINS WITH BINDING CAPABILITY TO LIGANDS - The present invention refers to a method for identifying hetero-multimeric ubiquitins with binding capability to a ligand. Furthermore, the invention provides DNA libraries encoding for a population of said hetero-multimeric ubiquitins as well as protein libraries obtained by expression of said DNA libraries, cells and phages containing said DNA or proteins, polynucleotides encoding for said fusion proteins and vectors comprising said polynucleotides. Further new binding proteins based on hetero-multimeric ubiquitin being able to bind specifically with high affinity to selected ligands are provided. | 2013-06-20 |
20130157879 | BIOMARKER DACT1 FOR GASTRIC CANCER - The present invention provides a method for diagnosing and determining prognosis of gastric cancer in a subject by detecting suppressed expression of the DACT1 gene, which in some cases is due to elevated methylation level in the genomic sequence of this gene. A kit and device useful for such a method are also provided. In addition, the present invention provides a method for treating gastric cancer by increasing DACT1 gene expression or activity. | 2013-06-20 |
20130157880 | METHODS AND USES RELATING TO THE IDENTIFICATION OF COMPOUND INVOLVED IN PAIN AS WELL AS METHODS OF DIAGNOSING ALGESIA - The present invention relates to a method of identifying a compound involved in pain, the use of Car3 nucleic acid or Car3 protein for identifying a compound involved in pain as well as methods of diagnosing algesia involving the same. | 2013-06-20 |
20130157881 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Coagulation factor VII, CA19-9, Insulin-like growth factor-binding protein 7, C—X—C motif chemokine 6, and C—C motif chemokine 13 as diagnostic and prognostic biomarkers in renal injuries. | 2013-06-20 |
20130157882 | Biomedical and Chemical Sensing with Nanobeam Photonic Crystal Cavities Using Optical Bistability - A miniature optical biosensor and biosensor array where high sensitivity for detection of biomolecular interaction does not require a fluorescent label. Non-linear frequency-shifts of optical resonators (‘nanobeams’) provide a digital all-or-nothing response to equilibrium binding of a biomarker to surface-immobilized bio-recognition elements, a signal suitable to identify active components in genetic and proteomic circuits, as well as toxic substances. The threshold level for the digital response is adjustable to accommodate for varying receptor affinities. A bistable cavity sensing (BCS) method can be used to track the shift of the resonance induced by the analyte more precisely than the conventional cavity sensing method, where the resolution is limited by the cavity linewidth. BCS method can be used to quantitate the concentration of the analyte, and their binding kinetics, affinities and etc. | 2013-06-20 |
20130157883 | Complex miRNA Sets as Novel Biomarkers for an Acute Coronary Syndrome - The present invention relates to single polynucleotides or sets of polynucleotides for detecting single miRNAs or sets of miRNAs for diagnosing and/or prognosing of an acute coronary syndrome in a blood sample from a human. Further, the present invention relates to means for diagnosing and/or prognosing of an acute coronary syndrome comprising said polynucleotides or sets of polynucleotides. Furthermore, the present invention relates to a method for diagnosing and/or prognosing of an acute coronary syndrome based on the determination of expression profiles of single miRNAs or sets of miRNAs representative for an acute coronary syndrome compared to a reference. In addition, the present invention relates to a kit for diagnosing and/or prognosing of an acute coronary syndrome comprising means for determining expression profiles of single miRNAs or sets of miRNAs representative for an acute coronary syndrome and at least one reference. | 2013-06-20 |
20130157884 | METHODS AND COMPOSITIONS INVOLVING MIRNA EXPRESSION LEVELS FOR DISTINGUISHING PANCREATIC CYSTS - Embodiments concern methods and compositions for evaluating a pancreatic cyst in a patient based on the expression levels of one or more miRNAs to determine whether the pancreatic cyst is a low or high risk lesion and in further need of treatment such as resection. | 2013-06-20 |
20130157885 | SYSTEM AND METHODS FOR SELECTIVE MOLECULAR ANALYSIS - Methods and systems for selectively amplifying a target DNA sequence in the presence of non-target DNA sequence in a sample, comprising: contacting the sample with an oligonucleotide system under hybridization conditions to form a reaction mixture including a forward primer and a reverse primer, wherein either the forward or reverse primer is modified to preferentially increase hybridization between the primer and the target sequence; cycling the hybridization of the oligonucleotide system so that, if the target DNA sequence is present in the sample, the primers hybridize to the target DNA sequence and the reaction mixture results in a first amplified product; and detecting the first amplified product. | 2013-06-20 |
20130157886 | METHODS OF DETECTING LUNG CANCER - Methods of lung cancer in a sample from a patient are provided. Methods of detecting changes in expression of one or more target RNAs associated with lung cancer are also provided. Compositions and kits are also provided. | 2013-06-20 |
20130157887 | DISCRETE STATES FOR USE AS BIOMARKERS - The present invention describes the use of discrete states and signatures for classifying samples. | 2013-06-20 |
20130157888 | DIAGNOSTIC AUTOANTIBODY PROFILES FOR THE DETECTION AND DIAGNOSIS OF NEURODEGENERATIVE DISEASES - The present invention provides methods, compositions, and kits for the detection of neurodegenerative disease specific autoantibodies for the diagnosis of neurodegenerative diseases and risk for developing neurodegenerative diseases, and for the generation of patient-specific neurodegenerative disease diagnostic autoantibody profiles. | 2013-06-20 |
20130157889 | DETECTION DEVICES AND RELATED METHODS OF USE - Disclosed are devices and methods for detecting analytes from a sample. | 2013-06-20 |
20130157890 | METHODS AND USES RELATING TO THE IDENTIFICATION OF COMPOUND INVOLVED IN PAIN AS WELL AS METHODS OF DIAGNOSING ALGESIA - The present invention relates to a method of identifying a compound involved in pain, the use of Ctla2b nucleic acid or Ctla2b protein for identifying a compound involved in pain as well as methods of diagnosing algesia involving the same. | 2013-06-20 |
20130157891 | ORGAN SPECIFIC DIAGNOSTIC PANELS AND METHODS FOR IDENTIFICATION OF ORGAN SPECIFIC PANEL PROTEINS - The present application provides novel compositions, methods, and assays for use in identification of appropriate diagnostic markers in blood. These compositions, methods, and assays are capable of distinguishing normal levels of detectable markers from changes in marker levels that are indicative of changes in health status. | 2013-06-20 |
20130157892 | ASSAY FOR MEASUREMENT OF ANTIBODIES BINDING TO A THERAPEUTIC MONOCLONAL ANTIBODY - Methods and system for determination of an anti- antibody (anti-AB) in vitro in a sample from a patient treated with a therapeutic monoclonal antibody (TmAB). Also, methods and systems for the determination of antigen specific antibodies of a particular immunoglobulin class and for the identification of a patient who is at risk of developing an adverse drug reaction (ADR) during treatment with a TmAB. | 2013-06-20 |
20130157893 | METHOD FOR PREDICTING THERAPEUTIC EFFECT OF IMMUNOTHERAPY ON CANCER PATIENT, AND GENE SET AND KIT TO BE USED IN THE METHOD - Provided is a gene set which is useful for predicting the therapeutic effect of an immunotherapy on a cancer patient. Also provided is a method for examining whether an immunotherapy is efficacious or not, said method comprising quantifying the expression amount of each of the genes constituting the aforesaid gene set. This examination method is useful for determining a therapeutic strategy for the cancer patient. | 2013-06-20 |
20130157894 | METHODS TO IDENTIFY COMBINATIONS OF NS5A TARGETING COMPOUND THAT ACT SYNERGISTICALLY TO INHIBIT HEPATITIS C VIRUS REPLICATION - The present invention is based on the surprising finding that pairs of HCV NS5A-targeting inhibitors can be identified which display similar resistance profiles yet, when combined, exhibit synergistic inhibition of wild type replicons and/or replicons carrying mutations conferring resistance to the HCV NS5A-targeting inhibitor. In addition, combinations of these molecules result in a higher genetic barrier to resistance, demonstrating their potential utility as novel combination therapies for treatment of HCV. | 2013-06-20 |
20130157895 | TISSUE STAINING METHOD, TISSUE EVALUATION METHOD AND BIOSUBSTANCE DETECTION METHOD - A tissue staining method which comprises: staining a tissue with a staining reagent wherein a biosubstance recognition site is bonded to particles carrying multiple fluorescent substances accumulated therein; in the stained tissue, counting fluorescent points or measuring fluorescent brightness; and evaluating the expression level of a biosubstance, which matches the biosubstance recognition site, in the aforesaid tissue on the basis of the number of the fluorescent points or fluorescent brightness that was measured. | 2013-06-20 |
20130157896 | ULTRATHIN CALCINATED FILMS ON A GOLD SURFACE FOR HIGHLY EFFECTIVE LASER DESORPTION/ IONIZATION OF BIOMOLECULES - A nanoscale calcinated silicate film fabricated on a gold substrate for highly effective, matrix-free laser desorption ionization mass spectrometry (LDI-MS) analysis of biomolecules. The calcinated film is prepared by a layer-by-layer (LbL) deposition/calcination process wherein the thickness of the silicate layer and its surface properties are precisely controlled. The film exhibits outstanding efficiency in LDI-MS with extremely low background noise in the low-mass region, allowing for effective analysis of low mass weight samples and detection of large biomolecules including amino acids, peptides and proteins. Additional advantages for the calcinated film include ease of preparation and modification, high reproducibility, low cost and excellent reusability. | 2013-06-20 |
20130157897 | METHOD AND APPARATUS FOR MAGNETIC STIRRING - A system for combinatorially processing a substrate is provided. The system includes a reactor or chemical library having a plurality of chambers defined within the reactor or library, the chambers operable to mix fluids disposed therein. A drive system is disposed below a bottom surface of the reactor. The drive system is operable to rotate a plurality of support plates below the surface of the substrate. The plurality of support plates has a non-circular shape. The non-circular shape of adjacent support plates includes extensions configured to traverse overlapping regions of rotation during rotation of adjacent support plates. Each of the extensions has a magnet disposed thereon. | 2013-06-20 |
20130157898 | PROBE, PROBE SET, PROBE CARRIER, AND TESTING METHOD - A probe, a set of probes, and a probe carrier on which the probe or the set of probes is immobilized, are provided for classification of fungus species. The probe or the set of probes is capable of collectively detecting fungus of the same species and distinguishingly detecting those fungus from fungus of other species. The probe is an oligonucleotide probe for detecting a pathogenic fungus DNA and includes at least one of base sequences of SEQ ID NOS. 1 to 4 and mutated sequences thereof. | 2013-06-20 |
20130157899 | REAGENTS AND METHODS RELATING TO DNA ASSAYS USING AMPLICON PROBES ON ENCODED PARTICLES - Encoded bead multiplex assays for chromosomal gains and losses are provided that provide the benefits of complex, large template DNA sources, such as BAC DNA, as the probe material without bead networking or other assay performance problems. Reagents for assaying DNA are described herein which include a plurality of encoded particles having attached amplicons amplified from a template DNA sequence. Each individual attached amplicon includes a nucleic acid sequence identical to a random portion of the template DNA sequence, wherein the amplicons together represent substantially the entire template DNA and wherein the nucleic acid sequence identical to a random portion of the template DNA sequence of each individual amplicon is shorter than the entire template DNA. | 2013-06-20 |
20130157900 | STRUCTURE-ACTIVITY RELATIONSHIPS - The present disclosure relates to compositions and methods for screening a plurality of polypeptide variants. | 2013-06-20 |
20130157901 | High Molecular Weight Low Polydispersity Polymers - The present invention relates to synthetic polymers having high molecular weight and low polydispersities, and methods of synthesis thereof. One embodiment of the present invention provides a method of polymerizing that includes dissolving acrylate monomers in a fluid media having an olefin-containing polyalcohol amide surfactant; and initiating a polymerization reaction of the acrylate monomers with a polymerization initiator to produce a polymer having a molecular weight of at least about 500,000 and a polydispersity index of about 1.25 or less. | 2013-06-20 |
20130157902 | High Molecular Weight Low Polydispersity Polymers - The present invention relates to synthetic polymers having high molecular weights and low polydispersities and methods of synthesis. In one embodiment of the present invention, a polymer includes a polyacrylate polymer obtained from a polymerization reaction in which the polyacrylate polymer has a molecular weight of at least about 500,000 and a polydispersity index of about 1.25 or less. | 2013-06-20 |
20130157903 | Spacer Fluids Containing Cement Kiln Dust and Methods of Use - Disclosed are spacer fluids comprising cement kiln dust (“CKD”) and methods of use in subterranean formations. | 2013-06-20 |
20130157904 | GREEN COAL BED METHANE FRACTURING FLUID COMPOSITIONS, METHODS OF PREPARATION AND METHODS OF USE - The invention describes improved environmentally friendly, non-toxic, CBM friendly, green fracturing compositions, methods of preparing fracturing compositions and methods of use. Importantly, the subject invention overcomes problems in the use of water-based mists as an effective fracturing composition particularly having regard to the ability of a mist to transport an effective volume of proppant into a formation. As a result, the subject technologies provide an effective economic solution to using high ratio gas fracturing compositions that can be produced in a continuous (i.e. non-batch) process without the attendant capital and operating costs of current pure gas fracturing equipment. | 2013-06-20 |
20130157905 | Method for the Removal or Suppression of Interfering Metal Ions Using Environmentally Friendly Competitive Binders - The present invention relates to environmentally friendly compositions and methods for removing or suppressing metal ions in waters, flowback waters, and produced waters to make such waters suitable for subsequent use in oil-field applications and for delinking metal cross-linked gelling agents. One embodiment of the present invention provides a method of providing a competitive binder and allowing the competitive binder to interact with interfering metal ions in a flowback fluid to suppress or remove interfering metal ions. | 2013-06-20 |
20130157906 | Nano-Sized Particle-Coated Proppants for Formation Fines Fixation in Proppant Packs - A fracturing fluid, gravel pack fluid and/or frac pack fluid containing particles such as proppants, gravel and/.or sand, may contain an effective amount of a nano-sized particulate additive to fixate or reduce fines migration, where the particulate additive is an alkaline earth metal oxide, alkaline earth metal hydroxide, alkali metal oxides, alkali metal hydroxides transition metal oxides, transition metal hydroxides, post-transition metal oxides, post-transition metal hydroxides piezoelectric crystals and pyroelectric crystals. The nano-sized particulate additive is optionally bound to the particles with a coating agent such as an oil, alcohol, glycol, glycol ethers, ketones, terpenes, etc. The particle size of the magnesium oxide or other agent may be nanometer scale but may be a larger scale than nanometer but still relatively small, which scale may provide unique particle charges that help fixate the formation fines. The carrier fluid used in the treating fluid may be aqueous, brine, alcoholic or hydrocarbon-based. | 2013-06-20 |
20130157907 | PROCESS FOR THE MANUFACTURE OF A GREASE COMPOSITION - Processes for the manufacture of metal complex grease compositions are provided. In one embodiment, the process comprises: preparing a slurry comprising a base oil, water, a metal base and a complexing agent, wherein the weight ratio of water:solid in the slurry is in the range of from 0.15:1 to 1.5:1; applying shear to the slurry; adding a C | 2013-06-20 |
20130157908 | GLYCEROL-CONTAINING FUNCTIONAL FLUID - A functional fluid comprising a major amount of an oil of lubricating viscosity, and at least about 0.05 wt-% glycerol. A method of preparing a functional fluid comprising adding glycerol to a functional fluid, wherein the glycerol is not glycerol monooleate. A method of preparing an additive concentrate comprising adding glycerol to a diluent oil wherein the concentrate contains from about 1% to about 99% by weight of said diluent. A method of reducing wear comprising contacting a metal surface with a functional fluid comprising a major amount of an oil of lubricating viscosity and at least about 0.05 wt-% glycerol. | 2013-06-20 |
20130157909 | Corrosion Inhibiting Polyalkylene Glycol-Based Lubricant Compositions - Lubricant compositions including a random or block copolymer first high-EO content polyalkylene glycol, a random copolymer second polyalkylene glycol based on propylene oxide and butylene oxide or a second polyalkylene homopolymer having propylene oxide or butylenes oxide units and at least one corrosion inhibitor selected from the group of sarcosines, amine phosphates, and calcium dinonylnaphthalenesulfonate/carboxylates are provided. Lubricant compositions for extreme conditions are also provided. | 2013-06-20 |
20130157910 | DIESEL ENGINE OILS - A lubricating oil additive composition comprising a first carboxylate detergent having a TBN of the actives of greater than about 200 to about 400; a second carboxylate detergent having a TBN of the actives of greater than about 60 to about 200; and at least one polyalkenyl succinimide | 2013-06-20 |
20130157911 | DIESEL ENGINE OILS - A lubricating oil additive composition comprising at least one carboxylate detergent wherein at least one of the carboxylate detergents has a TBN of the actives of greater than about 60 to about 200; at least one polyalkenyl succinimide; a first phenate detergent having a TBN of the actives of greater than about 60 to about 200; and a second phenate detergent having a TBN of the actives of greater than about 200 to about 400. | 2013-06-20 |
20130157912 | TRUNK PISTON ENGINE LUBRICATING OIL COMPOSITIONS - Disclosed herein is a trunk piston engine lubricating oil composition comprising (a) a major amount of an oil of lubricating viscosity; (b) one or more carboxylate-containing detergents comprising a salt of an alkyl-substituted hydroxyaromatic carboxylic acid, wherein at least about 50% of the alkyl moiety of the alkyl-substituted hydroxyaromatic carboxylic acid comprises C | 2013-06-20 |
20130157913 | PREPARATION OF A POST-TREATED MOLYBDENUM AMIDE ADDITIVE COMPOSITION AND LUBRICATING OIL COMPOSITIONS CONTAINING SAME - The invention is directed to oil soluble additive compositions, lubricating oil compositions, and additive concentrates comprising the salt of (1) a molybdenum oxide, sulfide, or oxysulfide; (2) an amide reaction product of a carboxylic acid component and a polyamine component wherein the charge mole ratio (CMR) of the carboxylic acid component to the polyamine component is about 2:1 to 1:1; and (3) a post-treating agent. | 2013-06-20 |
20130157914 | Lubricating Composition Containing an Antiwear Agent - The invention provides a lubricating composition containing an oil of lubricating viscosity and a compound obtained/obtainable by a process comprising reacting a glycolic acid, a 2-halo-acetic acid, or a lactic acid, or an alkali or alkaline metal salts thereof, (typically glycolic acid or a 2-halo-acetic acid) with at least one member selected from the group consisting of an amine, an alcohol, and an aminoalcohol. The invention further relates to the use of the lubricating composition in an internal combustion engine. | 2013-06-20 |
20130157915 | GREASE COMPOSITION FOR HUB UNIT BEARING - The invention provides a grease composition for huh unit bearing, containing (a) an aromatic diurea thickener, (b) a base oil, (c) a metal salt of oxidized wax, (d) diphenyl hydrogen phosphate, and (e) at least one rust preventive selected from the group consisting of sulfonate rust preventives and carboxylic acid rust preventives. The grease composition of the invention shows excellent anti-fretting properties at low temperature, and at the same time, exhibit excellent rust preventing properties. | 2013-06-20 |
20130157916 | Low Temperature Performance Lubricating Oil Detergents and Method of Making the Same - The present invention is directed to a method for preparing an unsulfurized, carboxylate-containing additive for lubricating oils and the product produced by said method, wherein said method comprises a) neutralization of a mixture of at least two alkyl phenols using an alkaline earth base in the presence of a promoter, to produce a mixture of alkyl phenates, wherein the mixture of at least two alkyl phenols comprises at least a first alkyl phenol wherein the alkyl group is derived from an isomerized alpha olefin and a second alkyl phenol wherein the alkyl group is derived from a branched chain olefin; (b) carboxylation of the mixture of alkyl phenates obtained in step (a) using carbon dioxide under carboxylation conditions sufficient to convert at least 20 mole % of the starting alkyl phenols to alkyl salicylate; and (c) removal of at least about 10% of the starting mixture of at least two alkyl phenols from the product produced in step (b) to produce said additive. | 2013-06-20 |
20130157917 | Industrial cleaning compositions and methods for using same - An environmentally-friendly cleaning composition for use in paper processing or recycling, which comprises in one embodiment (a) a blend of dibasic esters, (b) one or more biodiesel components (c) and, optionally, water or an additional component. The dibasic esters can be derived from a blend of adipic, glutaric, and succinic diacids, or isomers of adipic acid. | 2013-06-20 |
20130157918 | Universal Synthetic Golf Club Cleaner and Protectant, Method and Product-by-Process to Clean, Protect Golf Club Faces and Rejuvenate Golf Clubs Grips - The club cleaner, conditioner and protectant comprises alpha-olefins, low-odor aromatic solvents; and at least one base oil selected from the base oil group consisting of Hydroisomerized high base oils and HT Severe Hydro-cracked Base oils; as well as other (optional) ingredients. Also disclosed is a method for producing this product and related product-by-process. This product uses a formulated cleaning mixture to clean and restore the face of the club while rejuvenating the grips. The invention when sprayed on the clubface removes foreign materials and when wiped dry protects the face of the clubs from harsh stains, caused by soils, grass and chemicals related to fertilizers. In experimental testing, the invention increases drive distances by reducing sidespin and increasing backspin. The club is left with a factory-like finish making it easy to wipe clean of soiling. The invention when applied to the grips restores the surface to the new feel. | 2013-06-20 |
20130157919 | AQUEOUS ALKALINE CLEANING COMPOSITIONS AND METHODS OF THEIR USE - Aqueous alkaline cleaning composition free from organic solvents and metal ion-free silicates, the said compositions comprising (A) a thioamino acid having at least one primary amino group and at least one mercapto group, (B) a quaternary ammonium hydroxide, (C) a chelating and/or corrosion inhibiting agent selected from the group consisting of aliphatic and cycloaliphatic amines having at least two primary amino groups, and aliphatic and cycloaliphatic amines having at least one hydroxy group, (D) a nonionic surfactant selected from the group of acetylenic alcohols, alkyloxylated acetylenic alcohols and alkyloxylated sorbitan monocarboxylic acid mono esters; the use of the alkaline cleaning composition for the processing of substrates useful for fabricating electrical and optical devices; and a method for processing substrates useful for fabricating electrical and optical devices making use of the said aqueous alkaline cleaning composition. | 2013-06-20 |
20130157920 | CLEANING, PURIFYING, TREATING, AND EXTRACTING COMPOSITIONS AND ASSOCIATED METHODS FOR UTILIZING THE SAME - A process for purifying extracted oil, byproducts, and wastewater, including the steps of: providing a composition having at least one solvent, an alkaline agent, a deflocculant, at least one surfactant selected from the group comprising an alkoxylated alcohol surfactant, an alkylamino-polyethoxy-sulfate surfactant, a polyether-phosphate ester surfactant, a surfactant that is a phosphate ester of an ethoxylated alcohol, and a surfactant that is a polyethyleneglycol monoaklyl ether, and a bonding agent; and associating the composition with at least one of extracted oil, byproducts, and wastewater—including, but not limited to, froth, middlings, tailings, mature fine tailings, solids, and combinations thereof. | 2013-06-20 |
20130157921 | ACIDIC GEL CLEANER WITH IMPROVED RINSING FROM A DRIED STATE - The rinsing performance of acidic gel cleaners comprising acid, surfactant and water is improved using a synergistic combination of two polymers consisting essentially of (a) copolymer having a quaternized monomer and (b) microbially-derived polysaccharide. In a preferred embodiment of the invention, the acidic gel cleaner includes (a) a copolymer having at least a diallyldimethylammonium chloride monomer or an acrylamidopropyltrimethylammonium chloride monomer, and (b) xanthan gum. The improved gel cleaners have the unique ability to be easily rinsed from a hard surface even if previously dried into a dry mass on the hard surface. | 2013-06-20 |
20130157922 | WATER-BASED GEL WITH LOW SYNERESIS - The present invention is a water-based carrageenan gel composition that exhibits remarkable resistance against syneresis and mottling, made possible by the addition of relatively small amounts of nonionic cellulose derivatives such as methyl hydroxyethyl cellulose. | 2013-06-20 |
20130157923 | SYNTHESIS OF A NOVEL ODORANT - A novel odorant of formula (I) wherein each of R | 2013-06-20 |
20130157925 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER - The present invention discloses anti-cancer compositions, and associated methods, including an anti-cancer composition comprising: a cellular energy inhibitor having the structure according to formula I | 2013-06-20 |
20130157926 | BORONATED POLYMERS - The present invention relates to a boronated polymer according to Formula (1): a process for making the boronated polymer according to Formula (1), drug 10 delivery systems, aggregates, nanoparticles and hydrogels comprising the boronated polymer according to Formula (1). | 2013-06-20 |
20130157927 | CYSTEINE CROSS-LINKED STRUCTURAL PEPTIDES - Compositions and methods are provided using fusion peptides comprising at least one multi-functional solubility tag having an effective number of cross-linkable cysteines residues. The multi-functional peptidic solubility tags facilitate efficient fusion peptide production, easier downstream processing of the fusion peptide, and provide functional surface properties when coupled to a target material while the cross-linkable cysteines provide enhanced durability when binding the fusion peptide to a target material. | 2013-06-20 |
20130157928 | NOCICEPTIN MIMETICS - The present invention relates to nociceptin peptide mimetics that have α-helical structures and bind to and modulate the opioid receptor-like-1 (ORL-1) receptor. The peptide mimetics are constrained cyclic nociceptin analogues which have either agonist or antagonist activity. Pharmaceutical compositions comprising the nociceptin peptide mimetics and methods of treating or preventing a disease or condition ameliorated by modulating the ORL-1 receptor are also described. | 2013-06-20 |
20130157929 | GLUCAGON ANALOGUES - The invention provides materials and methods for promoting weight loss or preventing weight gain and for treating diabetes and associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptide compounds effective in such methods. The compounds may mediate their effect by having, for example, increased selectivity for the GLP-1 receptor compared to human glucagon. | 2013-06-20 |
20130157930 | LINEAR POLYESTERAMIDES FROM AMINOPHENOLIC ESTERS - The present invention is directed to linear, biodegradable polyesteramide (PEA) polymers synthesized with repeating units derived from aminophenol esters and diacids. These PEAs have a monomer repeat represented by | 2013-06-20 |
20130157931 | MITOCHONDRIAL PENETRATING PEPTIDES AS CARRIERS FOR ANTIMICROBIALS - There is described herein compounds comprising a mitochondrial penetrating peptide (MPP) conjugated to an antimicrobial, and their method of use. | 2013-06-20 |
20130157933 | ALBUMIN FUSION PROTEINS - The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating or preventing diseases, disorders or conditions related to diabetes mellitus using albumin fusion proteins of the invention. | 2013-06-20 |
20130157934 | Glucagon Superfamily Peptides Exhibiting Glucocorticoid Receptor Activity - Provided herein are glucagon superfamily peptides conjugated with GR ligands that are capable of acting at a glucocorticoid receptor. Also provided herein are pharmaceutical compositions and kits of the conjugates of the invention. Further provided herein are methods of treating a disease, e.g., a metabolic disorder, such as diabetes and obesity, comprising administering the conjugates of the invention. | 2013-06-20 |
20130157935 | GLUCAGON ANALOGUES - The invention provides materials and methods for promoting weight loss or preventing weight gain without affecting glycemic control. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon. | 2013-06-20 |
20130157936 | MODULATION OF GHRELIN LEVELS AND GHRELIN/UNACYLATED GHRELIN RATIO USING UNACYLATED GHRELIN - A method and a composition for decreasing ghrelin levels and/or decreasing ghrelin/unacylated ghrelin ratio in a subject, the method comprising administering an effective amount of unacylated ghrelin, a fragment thereof, an analog thereof and/or pharmaceutically acceptable salts thereof to the subject wherein a reduction in ghrelin levels and/or a reduction in ghrelin/unacylated ghrelin ratio is beneficial to the subject. Also, use of ghrelin level and/or ghrelin/unacylated ghrelin ratio as biomarkers for determining a subject's likelihood of responding to and/or benefiting from administration of unacylated ghrelin. | 2013-06-20 |
20130157937 | STABLE HIGH LIPID LIQUID FORMULA - The present invention provides a ketogenic diet in the form of a sterile shelf stable ready to use formula, in particular a tube feed, comprising casein and dietary fibre. | 2013-06-20 |
20130157938 | Insulin Derivatives Containing Additional Disulfide Bonds - The present invention is related to insulin derivatives containing additional disulfide bonds and methods of making such. | 2013-06-20 |
20130157939 | COMPOSITIONS FOR GASTRIC DELIVERY OF ACTIVE AGENTS - The present invention relates to compositions, including pharmaceutical compositions for oral administration, comprising: at least one therapeutically active agent; at least one surface active agent; at least one ester of poly-carboxylic acid and/or at least one ester of an aromatic carboxylic acid; and a non-aqueous medium, for use in the gastric absorption of said at least one therapeutically active agent of the composition and methods of oral administration of at least one therapeutically active agent utilizing compositions of the invention. | 2013-06-20 |
20130157940 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES - The present invention is directed to novel substituted aminotetrahydropyrans of structural formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved. | 2013-06-20 |
20130157941 | AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES - The present invention relates to azolopyridin-3-one derivatives of the general formula (I) with the meanings specified in the description, to their pharmaceutically usable salts and to their use as drug substances. | 2013-06-20 |
20130157942 | STABILIZED INSULINOTROPIC PEPTIDES AND METHODS OF USE - The present invention provides stably cross-linked insulionotropic polypeptides having superior and un-expected benefits in the treatment of conditions involving abnormal glucose homeostasis, e.g., type 2 diabetes and conditions relating to type 2 diabetes. Such benefits include, but are not limited to, extended polypeptide half-life, enhanced alpha-helicity, improved thermal stability and protease resistance, increased functional activity and pharmacologic properties, improved bioavailability when administered by any route, and improved bioavailability and gastrointestinal absorption when delivered orally, as compared to the corresponding unmodified polypeptides. The invention also provides compositions for administering the polypeptides of the invention, as well as methods for pre-paring and evaluating the polypeptides of the invention. | 2013-06-20 |
20130157943 | METHOD AND USE OF PEPTIDE ANTAGONISTS OF ZONOLIN TO PREVENT OR DELAY THE ONSET OF DIABETES - A method for preventing or delaying the onset of autoimmune diseases is disclosed. | 2013-06-20 |
20130157944 | Treatment of Myocardial Infarction and Vascular Injury with Netrin-1 - Disclosed herein are methods for treating, inhibiting, or reducing ischemia/reperfusion injury of a cardiac tissue; increasing phosphorylation of ERK1/2 and/or eNOS in a cardiac tissue; treating, inhibiting, or reducing loss of NO; treating, inhibiting, or reducing uncoupling of NOS; increasing recoupling of NOS; treating, inhibiting, or reducing loss of DCC protein and mRNA expression in a cardiac tissue; decreasing or reducing the infarct size of a heart resulting from ischemia/reperfusion injury; decreasing or reducing superoxide production by a cardiac tissue caused by ischemia/reperfusion injury; treating, inhibiting, or reducing neointimal formation and restenosis; treating, inhibiting, or reducing apoptosis of mobilized endothelial progenitor cells; or a combination thereof of a blood vessel (such as an artery, a coronary artery, a vein, or a capillary) or a portion of the blood vessel in a subject which comprise the administration of netrin-1. | 2013-06-20 |
20130157945 | PEPTIDES TARGETING TNF FAMILY RECEPTORS AND ANTAGONIZING TNF ACTION, COMPOSITIONS, METHODS AND USES THEREOF - The present invention provides modulators of TNF, particularly peptides and their derivatives, particularly GEP peptides, which antagonize TNF and TNF-mediated responses, activity or signaling. The invention provides methods of antagonizing TNF and the modulation of TNF-mediated diseases or responses, including inflammatory diseases and conditions. Compositions of GEP peptides, including in combination with other inflammatory mediators, are provided. Methods of treatment, alleviation, or prevention of TNF-mediated diseases and inflammatory conditions, including rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, inflammatory bowel diseases, Chrohn's disease, ulcerative colitis, uveitis, inflammatory lung diseases, chronic obstructive pulmonary disease, are provided. | 2013-06-20 |
20130157946 | NEUROTROPHIC PEPTIDES - The present invention relates to a neurotrophic peptide having an amino acid sequence of VGDGGLFEKKL (SEQ ID NO: 1) and alternatively comprising an adamantyl group at the C- and/or N-terminal end. The neurotrophic peptide can rescue cognition, correct impairments in neural cell proliferation and synaptic plasticity, and thus address the cognitive defects associated with Alzheimer's disease. | 2013-06-20 |
20130157947 | COMPOUNDS FOR STEM CELL DIFFERENTIATION - Small molecule compounds and methods for stem cell differentiation are provided herein. An example of a class of compounds that may be used to practice the methods disclosed herein is represented by enantiomerically pure isomers of compounds of Formula I: | 2013-06-20 |
20130157948 | BISPECIFIC EGFR/IGFIR BINDING MOLECULES - The present invention relates to bispecific molecules comprising an EGFR binding domain and a distinct IGFIR binding domain for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins. Exemplary bispecific molecules include antibody-like protein dimers based on the tenth fibronectin type III domain. | 2013-06-20 |
20130157949 | Novel Peptides for Wound Healing - The present invention relates to new peptides, pharmaceutical composition and cosmetic composition comprising them and their use for wound healing. | 2013-06-20 |
20130157950 | METHOD FOR TREATING AND/OR PREVENTING NEURODEGENERATIVE DISEASE BY ADIPONECTIN RECEPTOR AGONIST - The present invention was accomplished for the purpose of developing a method for effectively treating and/or preventing synucleinopathies, and is based on a discovery that an adiponectin receptor agonist suppresses α (alpha)-synuclein aggregation, tau phosphorylation and a decrease in proteasomal activity. | 2013-06-20 |
20130157951 | Pharmaceutical Composition Containing Goserelin for In-Situ Implant - The present invention provides a pharmaceutical composition capable of forming in-situ implant comprising goserelin or its pharmaceutically acceptable salts thereof, biodegradable polymer and a biocompatible organic solvent wherein the biocompatible organic solvent is miscible to dispersible in aqueous medium or body fluid. The present invention further provides a process for the preparation of pharmaceutical composition capable of forming in-situ implant. A kit containing composition for in-situ implant is provided comprising a first vial comprising a composition comprising a biodegradable polymer and a biocompatible organic solvent; wherein the biocompatible organic solvent is miscible to dispersible in aqueous medium or body fluid; and a second vial comprising goserelin acetate. | 2013-06-20 |
20130157952 | GENOMIC MARKERS FOR PREDICTION OF LONG-TERM RESPONSE TO GROWTH HORMONE (GH) THERAPY - The present invention relates to the use of genetic markers to identify the response to growth hormone treatment in Growth Hormone Deficiency (GHD) or Turner Syndrome (TS) patients as well as a method of treating GHD or TS patients and kits for genotyping. | 2013-06-20 |
20130157953 | TREATMENT OF CARDIAC CONDITIONS - The invention relates to the treatment of cardiac dysfunction. In particular, certain compounds, believed to be glucagon-GLP-1 dual agonist compounds, exert a positive inotropic effect while preserving the energy balance of the heart, and so may be superior to known inotropic agents such as dobutamine, norepinephrine and glucagon. | 2013-06-20 |
20130157954 | METHODS FOR TREATMENT OR PROPHYLAXIS OF KIDNEY OR LIVER DYSFUNCTION - Methods are provided for treatment or prophylaxis of liver or kidney dysfunction in individuals experiencing one or more of intestinal failure, short bowel syndrome or parenteral nutrition by the administration of GLP-2 or GLP-2 analogs. | 2013-06-20 |
20130157955 | METHOD OF DRUG DELIVERY FOR BONE ANABOLIC PROTEIN - The present invention provides a storage-stable composition containing a parathyroid hormone-related protein (PTHrP) and methods of using a PTHrP and the PTHrP compositions described herein to treat osteoporosis, to increase bone mass or to increase bone quality. The composition is storage stable, in sterile form, and in general may be stored at room temperature for at least several weeks to allow convenient parenteral administration to human patients. | 2013-06-20 |
20130157956 | BIOCOMPATIBLE COMPOSITIONS FOR TISSUE AUGMENTATION - A crosslinked gelatin hydrogel composition for tissue augmentation. | 2013-06-20 |
20130157957 | Moisturizing Composition Comprising an Aminopeptide Mixture - The invention is directed to skin moisturizing compositions comprising an aminopeptide mixture. The composition replenishes the skins natural moisturization factor and delivers excellent sensory benefits. The composition is not unpleasantly viscous during and after application. | 2013-06-20 |
20130157958 | DIAGNOSIS OF COWDEN AND COWDEN-LIKE SYNDROME BY DETECTION OF DECREASED KILLIN EXPRESSION - A method of diagnosing Cowden syndrome (CS) and Cowden-like Syndrome (CLS) is described. The method includes diagnosing CS and CLS in a subject by identifying a decrease in expression of the KILLIN gene, or by identifying hypermethylation of the KILLIN promoter region. Kits for diagnosing CS and CLS by identifying subjects having KILLIN promoter region hypermethylation and primers specific for a methylated KILLIN promoter region are also described. | 2013-06-20 |
20130157959 | USE OF HADES AS TUMOR SUPPRESSOR TARGET - The present invention relates to a new use of Hades as a tumor suppressor target, more particularly to a composition for suppressing tumor comprising an expression or action inhibitor of Hades protein having an amino acid sequence of SEQ ID NO: 2 as an effective ingredient. The present inventors have found that the overexpressed Hades protein interacts with p53 to inhibit the exonuclear mechanism of p53 and the knowdown of Hades induces increase in the expression of p53, demonstrating that Hades is a negative regulator to p53. Therefore, it would be understood that the inhibition of Hades overexpressed in tumor cells contributes to tumor-supressive effects of p53. The drug candidates capable of modulating the expression of the Hades protein, inhibiting the actions of the Hades protein or inhibiting interecation between Hades and p53 are considered a promising anticancer drug. | 2013-06-20 |
20130157960 | NOVEL AURISTATIN DERIVATIVES AND USE THEREOF - The present application relates to novel derivatives of monomethylauristatin F, to processes for preparing these derivatives, to the use of these derivatives for treating and/or preventing diseases, and also to the use of these derivatives for preparing medicaments for treating and/or preventing diseases, more particularly hyperproliferative and/or angiogenic disorders such as, for example, cancerous disorders. Such treatments may be practised as a monotherapy or else in combination with other medicaments or further therapeutic measures. | 2013-06-20 |
20130157961 | LYTIC-PEPTIDE-HER2/NEU (HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2) LIGAND CONJUGATES AND METHODS OF USE - The invention relates to conjugates that bind to Her2/neu, methods of using conjugates that bind to Her2/neu and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies that express Her2/neu. | 2013-06-20 |
20130157962 | METHODS FOR INHIBITING GROWTH OF PROLACTIN-RESPONSIVE CANCER CELLS WITH CYCLOSPORINE A OR OTHER CYCLOPHILIN INHIBITORS - Methods are provided for inhibiting growth of prolactin-responsive cancer cells and treating prolactin-responsive malignancies via administration an agent such as cyclosporine A which directly inhibits an enzymatic activity of a cyclophilin. | 2013-06-20 |
20130157963 | OPHTHALMIC COMPOSITIONS COMPRISING POLYVINYL CAPRALACTAM-POLYVINYL ACETATE-POLYETHYLENE GLYCOL GRAFT COPOLYMERS - Compositions and methods related to ophthalmic use of polyvinyl capralactam-polyvinyl acetate-polyethylene glycol graft copolymers and therapeutic uses are described herein. | 2013-06-20 |
20130157964 | Blockade Of Inflammatory Proteases With Cyclic Peptides - Drug compositions for treatment of one or more inflammatory conditions can includes at least one of a θ-defensin, analog or derivative thereof. Inventive methods include researching θ-defensins, analogs or derivatives thereof for their efficacy with respect to anti-inflammatory effects, and providing such compositions to the marketplace for the purpose of treating inflammatory conditions. Of particular interest are drug compositions effective to produce clinically relevant inhibition of tumor necrosis factor alpha (TNF-α)-converting enzyme (TACE) or other proinflammatory proteases, and/or sheddases. it is contemplated that preferred compositions can be used to treat rheumatoid arthritis, inflammatory bowel disease, and other chronic inflammatory diseases, autoimmune diseases, cancer, and Alzheimer's, osteoarthritis, inflammation-related neurodegenerative and other inflammation-related diseases. | 2013-06-20 |
20130157965 | Prevention and Treatment of Oxidative Stress Disorders by Glutathione and Phase II Detoxification Enzymes - The present invention generally relates to the field of treating oxidative stress disorders by administering a pharmaceutically effective amount of a compound that elevates the intracellular levels of glutathone or intracelluar levels of at least one Phase II detoxification enzyme in animal tissue. The present invention also relates to the field of protecting a subject from oxidative stress disorders by administering a pharmaceutically effective amount of a compound that elevates the intracellular levels of glutathone or intracelluar levels of at least one Phase II detoxification enzyme in the subject. The present invention also relates to a pharmaceutical composition useful for the treatment of oxidative stress disorders. | 2013-06-20 |
20130157966 | NEW USE OF ICARIIN AND EPIMEDIUM FLAVONOIDS CONTAINING ICARIIN - New use of icariin and Epimedium flavaoids containing icariin is provided by the present invention. Specifically, uses of compounds of Formula I or Epimedium containing compounds of formula I, Epimedium flavanoids, or extracts of Epimedium in manufacturing medicaments for treating, preventing, reducing and/or relieving diseases and/or conditoins related to neural myelin sheath impairments, or use of above materials in manufacturing medicaments for relieving demyelination and/or promoting repair of myelin sheath are provided by the present application, wherein, R | 2013-06-20 |
20130157967 | Use Of A Phospholipid-Containing Composition For The Removal Of Subcutaneous Fat Accumulations By Subcutaneous Lipolysis - The invention described herein relates to the use of an aqueous composition containing at least one phospholipid. at least one glycyrrhizic acid or salts of glycyrrhizic acid for the manufacture of mediciments for the removal of subcutaneous fat accumulation. | 2013-06-20 |
20130157968 | COSMETIC COMPOSITION - The invention relates to novel eucomic acid (2-(4-hydroxybenzyl)malic acid) derivatives or plant extracts comprising such derivatives, and also to cosmetic or dermatological compositions containing these compounds or these extracts, and to cosmetic care methods using said compositions. Exemplary compounds are represented by formula (I) below: | 2013-06-20 |
20130157969 | POLYOL MODIFIED AMINOGLYCOSIDE-LIPID CONJUGATES - In some aspects, the present invention provides aminoglycoside derivatives thereof that exhibit antibacterial activity. In some aspects, the aminoglycoside derivatives comprise compounds consisting of (a) an ammoglycoside group and (b) at least one hydrophobic carbamate and alkoxy group to the primary or secondary hydroxy position of the aminolvcoside group and salts thereof. Additionally, methods of treating and preventing bacterial infections using the aminoglycoside derivatives are also provided | 2013-06-20 |